Category: Boston Scientific
Here's a look at some of the top Wall Street stories for medical device companies this week: Medtronic updates on $43B Covidien deal financing; Boston Scientific, Bard CEOs cool on consolidation; Nevro sets range for IPO of up to $106m; Alere to sell Alere Health unit to Optum for $600m; Skyline Medical conducts 1-for-75 reverse stock split
Here's a look at some of the top regulatory stories for medical device companies this week: Boston Scientific wins CE Mark, FDA nod for spinal surgical leads; ReFlow has new Wingman35 in U.S. market; Auditors: FDA needs to boost cybersecurity; Life Spine creates Centric Medical ankle & foot unit
Here's a look at some of the top legal news stories for medical device companies this week: Ex-Boston Scientific engineer accused of stealing balloon catheter secrets; Jury clears DePuy in 1st Pinnacle bellwether trial; U.S. Patent Office denies Medtronic request in Endotach stent case; Jury deliberations begin in first trial over DePuy's Pinnacle hips; Johnson & Johnson's DePuy wins first trial over Pinnacle hips
A look at the top 10 politicial action committee donations shows that medtech is betting heavily on a GOP win in the midterm elections.
The medical device industry is betting on a Republican sweep of the U.S. Congress during the 2014 mid term elections, according to a MassDevice.com analysis of donations made by the industry's 10 largest political action committees.
The CEOs of medical device companies Boston Scientific and C.R. Bard are cool on the consolidation trend in medtech, saying they don't see the need for mega-deals to grow their businesses.
Sales of its cardiac rhythm management devices help boost Boston Scientific above expectations for the 3rd quarter.
Boston Scientific says its CoverEdge 32 and CoverEdge X 32 surgical leads won CE Mark approval in the European Union and pre-market approval from the FDA for use with its Precision Spectra spinal cord stimulator.